Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02160340 · ClinicalTrials.gov registry record
Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older
A clinical trial, sponsored by Nova Southeastern University.
- Completed
- Registry status
- 1,584
- Enrollment target
NCT02160340: Completed study, sponsored by Nova Southeastern University.
NCT02160340 is a clinical trial that has completed, run by Nova Southeastern University. The registered enrollment target is 1,584 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02160340 has completed, sponsored by Nova Southeastern University.
- COMPLETED
- Registry status
- 1,584 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the prevalence of vitreomacular adhesion (VMA) in patients 40 years and older using Spectral Domain Optical Coherence Tomography.
Primary Outcome
Prevalence will be measured using Spectral Domain Optical Coherence Tomography. Tomography scans will be evaluated for the presence or absence of vitreomacular adhesion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,584 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-05 |
What the finished NCT02160340 record still lists
NCT02160340 is an observational study that tracks outcomes without assigning an intervention. Its 1,584 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02160340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02160340 about?
NCT02160340 is a clinical study titled "Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older". The purpose of this study is to evaluate the prevalence of vitreomacular adhesion (VMA) in patients 40 years and older using Spectral Domain Optical Coherence Tomography.
What is the current status of trial NCT02160340?
This trial is currently completed. The enrollment target is 1,584 participants. The study started on 2014-05. Estimated completion is 2017-05.
Who is sponsoring clinical trial NCT02160340?
This trial is sponsored by Nova Southeastern University, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia